Dr. Rice is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2781 Crystal Woods Dr
Finksburg, MD 21048Phone+1 410-259-7939Fax+1 717-334-0929
Summary
- Dr. Robert Rice is an oncologist based in Finksburg, MD, specializing in hematologic oncology. He completed his residency in internal medicine at Case Western Reserve University and his fellowship in hematology and medical oncology at Vanderbilt University Medical Center. Most recently, he served as the Executive Medical Director at Luminis Health. Dr. Rice has expertise in conditions such as amyloidosis, hereditary breast/ovarian cancer, myelodysplasia, and myelofibrosis. He has several published research papers, with topics including Cdc25 phosphatase inhibitors, and his work has been cited multiple times in the scientific community.
Education & Training
Vanderbilt University Medical CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 2000 - 2003
University of Pittsburgh School of MedicineClass of 2000
Certifications & Licensure
CO State Medical License 2024 - 2027
AZ State Medical License 2024 - 2026
ID State Medical License 2024 - 2026
MT State Medical License 2024 - 2026
MD State Medical License 2006 - 2025
NV State Medical License 2024 - 2025
OH State Medical License 2023 - 2025
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
- Join now to see all
Publications & Presentations
PubMed
- 20 citationsIdentification of new Cdc25 dual specificity phosphatase inhibitors in a targeted small molecule array.Alexander P. Ducruet, Robert L. Rice, Kenji Tamura, Fumiaki Yokokawa, Shiho Yokokawa
Bioorganic & Medicinal Chemistry. 2000-06-01 - 19 citationsDual G1 and G2/M phase inhibition by SC-ααδ9, a combinatorially derived Cdc25 phosphatase inhibitorKenji Tamura, Robert L. Rice, Peter Wipf, John S. Lazo
Oncogene. 1999-11-25 - 17 citationsCell cycle dependent subcellular distribution of Cdc25B subtypes.Elizabeth S. Woo, Robert L. Rice, John S. Lazo
Oncogene. 1999-04-29
Professional Memberships
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
